Clinical Trial Update: Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia [EARLY_Phase 1]

View source ↗

Summary

Early-phase clinical trial evaluating induced pluripotent stem cell-derived natural killer cells for refractory or relapsed acute myeloid leukemia; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Induced pluripotent stem cell-derived natural killer cells therapy

Snippet

Sponsor: Guangzhou Ruixin Biotechnological Co., LTD | Conditions: Acute Myeloid Leukemia (AML) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING